Article
Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder.
Depression and anxiety - 1 May 2010
Coric Vladimir, Feldman Howard H, Oren Dan A, Shekhar Anantha, Pultz Joseph, Dockens Randy C, Wu Xiaoling, Gentile Kimberly A, Huang Shu-Pang, Emison Eileen, Delmonte Terrye, D'Souza Bernadette B, Zimbroff Daniel L, Grebb Jack A, Goddard Andrew W, Stock Elyse G
Abstract excerpt
BACKGROUND: Antagonism of corticotropin-releasing factor (CRF) receptors has been hypothesized as a potential target for the development of novel anxiolytics. This study was designed to determine the safety and efficacy of pexacerfont, a selective CRF-1 receptor antagonist, in the treatment of generalized anxiety disorder (GAD). METHOD: This was a multicenter, randomized, double-blind, placebo-controlled and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.